Publications

ssessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.

Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk . and Cholesterol Treatment Trialists' (CTT) Collaboration ., (2026), Lancet

SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.

Neuen BL. et al, (2026), JAMA, 335, 233 - 244

Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis.

Staplin N. et al, (2026), JAMA, 335, 220 - 232

Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Zhu D. et al, (2025), Am J Kidney Dis

"Hi"s and "Lo"s of Targeting Serum Phosphate Levels in Hemodialysis.

Mayne KJ. and Herrington WG., (2025), J Am Soc Nephrol, 36, 2328 - 2329

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.

Herrington WG. et al, (2025), Lancet Diabetes Endocrinol, 13, 1003 - 1014

n application of the MR-Horse method to reduce selection bias in genome-wide association studies of disease progression.

Donovan K. et al, (2025), Eur J Hum Genet, 33, 1677 - 1683

In CKD, electronic letter nudges for patients or providers did not increase RASi or SGLT2i prescriptions at 6 mo.

Turnbull I. et al, (2025), Ann Intern Med, 178

Polygenic prediction of coronary heart disease among 130,000 Mexican adults.

Liu T. et al, (2025), Eur J Prev Cardiol

Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.

Turner M. et al, (2025), Hypertension, 82, 1896 - 1905

Glucose Interference in Urine Biomarkers and Implications for Sodium-Glucose Cotransporter 2 Inhibition.

Malijan GB. et al, (2025), Kidney Int Rep, 10, 4090 - 4093

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.

Malijan GB. et al, (2025), Am J Kidney Dis

Lancet Seminar Chronic kidney disease

HERRINGTON W. et al, (2025), The Lancet

Key priorities for the implementation of the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes in low-resource settings.

Marx N. et al, (2025), Eur Heart J Qual Care Clin Outcomes, 11, 868 - 874

Individual Participant Level Meta-Analysis Of The Effects Of Empagliflozin On Conventional And Exploratory Acute And Chronic Kidney Outcomes

HERRINGTON W. et al, (2025), The Lancet Diabetes and Endocrinology

Search results (203)